Sangamo Therapeutics

Mark McClung, Chief Business Officer and EVP
Brisbane, CA
Sangamo Therapeutics is focused on translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, in vivo genome editing, and gene regulation.

By using this website you agree to accept our Privacy Policy and Terms & Conditions